SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
SKOKIE, Ill., Feb. 12, 2016 -- Exicure is pleased to announce that Chad A. Mirkin, Ph.D., co-founder and director of Exicure, has been named the recipient of the 2016 Dan David Prize in the Future Time Dimension. Dr. Mirkin is being awarded the prize for his ground-breaking contributions to the field of nanoscience. His work led to the invention of 3-D structures called spherical nucleic acids (SNAs) which are currently being developed by Exicure. The prize will be presented on Sunday, May 22, 2016, at Tel Aviv University in Tel Aviv, Israel.
“The Dan David Prize recognizing Chad Mirkin’s work is continued validation of the SNA technology’s great potential to fulfill the promise of nucleic acid therapeutics in organs beyond the liver,” said Dr. David Giljohann, Chief Executive Officer of Exicure. “This is another high honor for Chad and for our SNA platform.”
The international Dan David Prize is awarded annually for outstanding contributions to humanity in three time dimensions: past, present, and future. This year, the future time dimension prize recognizes proven, exceptional, and distinct excellence in the field of nanoscience.
About Spherical Nucleic Acids
SNAs are nanoscale, spherical arrangements of densely packed and radially oriented nucleic acids. This architecture overcomes one of the most difficult obstacles to nucleic acid based therapeutics: safe and effective delivery into cells and tissues of therapeutic importance without the need for additional physical or chemical methods or components. The SNAs can be designed to be extremely potent and highly targeted gene regulation and immune-modulatory agents.
About Exicure
Exicure, formerly AuraSense Therapeutics, is developing a new class of immunomodulatory and gene-silencing drugs against validated targets. Our 3-D, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatory disorders to oncology.
Media Contact: Karen Sharma MacDougall Biomedical Communications 781-235-3060 [email protected]
